Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2088-2093

  Choi, C M ^a   Yang, S C ^b   Jo, H J ^c   Song, S Y ^d   Jeon, Y J ^e   Jang, T W ^f   Kim, D J ^g   Jang, S H ^h   Yang, S H ⁱ   Kim, Y D ^j   Lee, K H ^k   Jang, S J ^a   Kim, Y T ^b   Kim, D K ^a   Chung, D H ^b   Kim, L ^l   Nam, H S ^l   Cho, J H ^l   Kim, H J ^l   Ryu, J S ^l  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Wonkwang University   (South Korea)

^d Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^e Keimyung University   (South Korea)

^f Kosin University   (South Korea)

^g Soonchunhyang University College of Medicine   (South Korea)

^h Hallym University   (South Korea)

ⁱ Wonkwang University Hospital   (South Korea)

^j Pusan National University School of Medicine   (South Korea)

^k Yeungnam University College of Medicine   (South Korea)

^l Inha University Hospital   (South Korea)

more..

Author keywords

DNA damage response; Non small cell lung cancer; Prognosis; Stage I

Indexed keywords

53BP1 PROTEIN; 53BP1PS25 PROTEIN; ATM PROTEIN; ATMPS1981 PROTEIN; BIOLOGICAL MARKER; BRCA1PS1423 PROTEIN; CHECKPOINT KINASE 2; CHK2PT68 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE H2AX; MDC1 PROTEIN; MDC1PS964 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DNA DAMAGE; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 84864925900     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr606     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2011; 60: 277-300.
2. Jung KW, Park S, Kong HJ et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011; 43: 1-11.
3. Felip E, Cedrés S, Checa E, Martinez P. How to integrate current knowledge in selecting patients for first line in NSCLC? Ann Oncol 2010; 21 (Suppl 7): vii230-vii233.
4. Konopa K. Do we have markers to select patients for adjuvant therapies of nonsmall-cell lung cancer? Ann Oncol 2010; 21 (Suppl 7): vii199-vii202.
5. Postmus PE. Screening for lung cancer, an ongoing debate. Ann Oncol 2008; 19 (Suppl 7): vii25-vii27.
6. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
7. Arriagada R, Auperin A, Burdett S et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two metaanalyses of individual patient data. Lancet 2010; 375: 1267-1277.
8. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-3559.
9. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
10. Nuciforo PG, Luise C, Capra M et al. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007; 28: 2082-2088.
11. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-913.
12. Bartkova J, Horejsi Z, Sehested M et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007; 26: 7414-7422.
13. Bonner WM, Redon CE, Dickey JS et al. GammaH2AX and cancer. Nat Rev Cancer 2008; 8: 957-967.
14. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-808.
15. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
16. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
17. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
18. Lee KH, Min HS, Han SW et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008; 60: 401-407.
19. Holm B, Mellemgaard A, Skov T, Skov BG. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009; 27: 4254-4259.
20. Zhao H, Albino AP, Jorgensen E et al. DNA damage response induced by tobacco smoke in normal human bronchial epithelial and A549 pulmonary adenocarcinoma cells assessed by laser scanning cytometry. Cytometry A 2009; 75: 840-847.
21. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
22. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
23. Lee E, Ryu J, Cho J et al. Comparison of face-to-face interview questionnaires and medical record data for smoking habit in lung cancer patients. Tuberc Respir Dis 2007; 62: 27-32.
24. Jacot W, Colinet B, Bertrand D et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008; 19: 1458-1464.
25. Olaussen KA, Soria JC. Validation of ERCC1-XPF immunodetection-letter. Cancer Res 2010; 70: 3851-3852.